Literature DB >> 17474072

Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping.

Maria B Asparuhova1, Gabriela Marti, Songkai Liu, Fatima Serhan, Didier Trono, Daniel Schümperli.   

Abstract

The HIV-1 regulatory proteins Tat and Rev are encoded by multiply spliced mRNAs that differ by the use of alternative 3' splice sites at the beginning of the internal exon. If these internal exons are skipped, the expression of these genes, and hence HIV-1 multiplication, should be inhibited. We have previously developed a strategy, based on antisense derivatives of U7 small nuclear RNA, that allows us to induce the skipping of an internal exon in virtually any gene. Here, we have successfully applied this approach to induce a partial skipping of the Tat, Rev (and Nef) internal exons. Three functional U7 constructs were subcloned into a lentiviral vector. Two of them strongly reduced the efficiency of lentiviral particle production compared to vectors carrying either no U7 insert or unrelated U7 cassettes. This defect could be partly or fully compensated by coexpressing Rev from an unspliced mRNA in the producing cell line. Upon stable transduction into CEM-SS or CEM T-lymphocytes, the most efficient of these constructs inhibits HIV-1 multiplication. Although the inhibition is not complete, it is more efficient in combination with another mechanism inhibiting HIV multiplication. Therefore, this new approach targeting HIV-1 regulatory genes at the level of pre-mRNA splicing, in combination with other antiviral strategies, may be a useful new tool in the fight against HIV/AIDS. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17474072     DOI: 10.1002/jgm.1027

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  16 in total

1.  Excessive RNA splicing and inhibition of HIV-1 replication induced by modified U1 small nuclear RNAs.

Authors:  Dibyakanti Mandal; Zehua Feng; C Martin Stoltzfus
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

Review 2.  Regulation of alternative splicing by short non-coding nuclear RNAs.

Authors:  Amit Khanna; Stefan Stamm
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

3.  U7 snRNA-mediated correction of aberrant splicing caused by activation of cryptic splice sites.

Authors:  Hideki Uchikawa; Katsunori Fujii; Yoichi Kohno; Noriyuki Katsumata; Kazuaki Nagao; Masao Yamada; Toshiyuki Miyashita
Journal:  J Hum Genet       Date:  2007-09-13       Impact factor: 3.172

Review 4.  Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy.

Authors:  Rachel Nlend Nlend; Kathrin Meyer; Daniel Schümperli
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 5.  A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground.

Authors:  Toshifumi Yokota; Shin'ichi Takeda; Qi-Long Lu; Terence A Partridge; Akinori Nakamura; Eric P Hoffman
Journal:  Arch Neurol       Date:  2009-01

Review 6.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

Review 7.  Progress toward therapy with antisense-mediated splicing modulation.

Authors:  Liutao Du; Richard A Gatti
Journal:  Curr Opin Mol Ther       Date:  2009-04

Review 8.  U7 snRNA: A tool for gene therapy.

Authors:  Ankur Gadgil; Katarzyna Dorota Raczyńska
Journal:  J Gene Med       Date:  2021-02-23       Impact factor: 4.565

9.  An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects.

Authors:  Eugenio Fernandez Alanis; Mirko Pinotti; Andrea Dal Mas; Dario Balestra; Nicola Cavallari; Malgorzata E Rogalska; Francesco Bernardi; Franco Pagani
Journal:  Hum Mol Genet       Date:  2012-02-23       Impact factor: 6.150

Review 10.  RNA and disease.

Authors:  Thomas A Cooper; Lili Wan; Gideon Dreyfuss
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.